These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31776598)

  • 1. [Licensing procedures for human vaccines in Germany and Europe and the WHO prequalification program].
    Grabski E; Hildt E; Wagner R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Jan; 63(1):4-15. PubMed ID: 31776598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks].
    Pfleiderer M; Wichmann O
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):263-73. PubMed ID: 25566841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chapter 22: Assuring the quality, safety and efficacy of HPV vaccines: the scientific basis of regulatory expectations pre- and post-licensure.
    Wood D; Shin JH; Duval B; Schmitt HJ
    Vaccine; 2006 Aug; 24 Suppl 3():S3/187-92. PubMed ID: 16950006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory constraints as seen from the pharmaceutical industry.
    Galligani G; David-Andersen I; Fossum B
    Dev Biol (Basel); 2005; 121():235-41. PubMed ID: 15962486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Regulatory Evaluation of Vaccines for Human Use.
    Baylor NW
    Methods Mol Biol; 2016; 1404():773-787. PubMed ID: 27076337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. History of regulatory requirements for poultry biologics in the United States, 1970s to 1990s.
    Espeseth DA; Lasher H
    Avian Dis; 2013 Jun; 57(2):167-71. PubMed ID: 24689169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory considerations for emergency use of non-USDA licensed vaccines in the United States.
    Hill RE; Foley PL; Carr MY; Elsken LA; Gatewood DM; Ludemann LR; Wilbur LA
    Dev Biol (Basel); 2003; 114():31-52. PubMed ID: 14677675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations.
    Weeke-Lüttmann M
    Eur J Epidemiol; 1994 Aug; 10(4):513-4. PubMed ID: 7843372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials.
    Black S
    Expert Rev Vaccines; 2015; 14(12):1543-8. PubMed ID: 26414015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.
    Lopalco PL; DeStefano F
    Vaccine; 2015 Mar; 33(13):1541-8. PubMed ID: 25444788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Regulatory aspects of the development, licensing, and availability of immunological veterinary medicinal products].
    JungbMck C; Werner E; Von Messling V
    Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):473-7. PubMed ID: 26697714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
    Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D
    PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using the impact of pneumococcal vaccines on nasopharyngeal carriage to aid licensing and vaccine implementation; a PneumoCarr meeting report March 27-28, 2012, Geneva.
    Goldblatt D; Ramakrishnan M; O'Brien K
    Vaccine; 2013 Dec; 32(1):146-52. PubMed ID: 23933374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.